A congressional investigation has revealed that FDA's controversial approval of Biogen's Alzheimer's drug Aduhelm was "rife was irregularities" that overlooked internal concerns about the drug's safety and efficacy—leading one expert to call it "the worst decision the FDA has ever made."
After a 19-year-old man developed "a strange rash on his arms and legs" and noticed blood in his urine, he learned that a platelet disorder was preventing his blood from clotting—and tests revealed a surprising trigger, Lisa Sanders writes for the New York Times Magazine.
FDA recently approved an updated label for the Plan B "morning after" pill that says the medication does not prevent the implantation of a fertilized egg in the uterus, in today's bite-sized hospital and health industry news from Arizona, Maryland, and Oregon.
Print All Daily Briefing Article from
Have a Question?
Ask our experts a question on any topic in health care by visiting our member portal, AskAdvisory.